Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial involved people with multiple sclerosis (MS) and ran in two phases. In the main (core) phase, 370 people received fingolimod at a higher dose (1.25 mg), 358 received it at a lower dose (0.5 mg), and 355 received a placebo (a dummy treatment with no active ingredient) — for a total of 1,083 participants. Some of these participants then continued into an extension phase, where those previously on placebo were switched to one of the two fingolimod doses. The trial was primarily measuring the average number of MS relapses (episodes of new or worsening symptoms) per year in each group over 24 months. The reported data shows that over the core 24-month phase, the estimated average number of relapses per year was 0.203 for the higher-dose group, 0.208 for the lower-dose group, and 0.403 for the placebo group. When relapse rates were calculated across the full study period (including the extension phase), the reported figures were 0.180, 0.192, and 0.363 respectively. The reported data also shows MRI brain scan measurements. Brain volume declined in all three groups over two years, with the placebo group showing a reported change of −1.279% compared to −0.595% (higher dose) and −0.858% (lower dose). The average number of new or newly enlarged areas of inflammation visible on MRI scans was reported as 1.6 (higher dose), 2.3 (lower dose), and 8.9 (placebo) over the first year. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 36286605) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Multiple Sclerosis Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You are a man or woman between the ages of 18 and 55 who has been diagnosed with multiple sclerosis
- Your multiple sclerosis follows a relapsing-remitting pattern, meaning you have flare-ups followed by periods of recovery
- Your level of disability, as measured by a standard MS scoring scale, falls within a certain range (a score of 0 to 5.5 — confirm with trial site if you are unsure of your score)
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You have another long-term condition affecting the immune system, cancer, a serious lung condition, heart failure, or similar serious health conditions
- You are currently pregnant or breastfeeding
- For a later stage (extension phase) of the trial: you must have completed the first 24 months of the study, and you would not be eligible if you had to stop taking the study drug during that time due to side effects, serious health events, or abnormal test results
- There may be additional requirements not listed here that the trial site will check (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial contact details on record
Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Australian sites
This trial is not accepting new participants. These are the contact details ClinicalTrials.gov holds for it, kept here for reference. They are not an invitation to enrol, and the sites listed may no longer be running this trial.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, including 1 in Australia. They are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Aggregate Annualized Relapse Rate (ARR) Estimate up to Month 24
Other options
Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.